

Detection and Treatment of Diabetic Urinary Microalbumin: The Need of the Hour

INTRODUCTION

Diabetic urinary microalbumin, also known as microalbuminuria, is a crucial marker in the progression of diabetes-related complications, particularly affecting the kidneys. Around one out of three adults progress to diabetic kidney disease, which is truly menacing. The detection and early intervention of this condition play a pivotal role in preventing severe renal damage and other cardiovascular complications. The early detection of diabetic urinary microalbumin is imperative for effective management and prevention of diabetic nephropathy. Regular screening for microalbuminuria is recommended for individuals with diabetes, as it often precedes the manifestation of overt nephropathy.^[1,2]

The gold standard for detecting microalbuminuria is the urinary albumin-to-creatinine ratio (UACR) measurement. A UACR value of 30–300 mg/g is indicative of microalbuminuria, while values exceeding 300 mg/g suggest macroalbuminuria and advanced kidney damage.^[3,4] Routine monitoring through urine tests allows for early identification and intervention, enabling physicians to implement timely treatment strategies.

TREATMENT STRATEGIES FOR DIABETIC URINARY MICROALBUMIN

Glycemic control

Maintaining optimal blood glucose levels is fundamental in preventing and managing diabetic complications, including microalbuminuria. Tight glycemic control through lifestyle modifications and drugs, including insulin, helps reduce the progression of kidney damage. Incretin-based therapeutic interventions, such as DPP-4 inhibitors and GLP-1 receptor agonists, have also been shown to have renoprotective effects besides glucose lowering. The key drug is essentially SGLT2 inhibitors,^[5] especially when combined with angiotensin receptor blockers.

Blood pressure management

Hypertension is a common comorbidity in individuals with diabetes and significantly contributes to the progression of diabetic nephropathy. Antihypertensive medications, particularly angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, play a crucial role in managing blood pressure and preventing further deterioration of renal function. Recent research has also identified finerenone, a mineralocorticoid receptor antagonist, as an agent that may be used to delay the progression of diabetic kidney disease.^[5] The use of taurine as an amino acid supplement is projected to prevent progression without robust evidence.^[6]

Lifestyle modifications

Encouraging lifestyle changes is essential for individuals with diabetic urinary microalbumin. These modifications include adopting a heart-healthy diet, engaging in regular physical activity, maintaining a healthy weight, and avoiding tobacco use. Lifestyle interventions^[7] not only contribute to glycemic control but also have positive effects on blood pressure and can supplement drug therapy in the prevention of diabetic kidney disease.

Dietary sodium restriction

Reducing dietary sodium intake is crucial in managing microalbuminuria, as excessive sodium can exacerbate hypertension and contribute to renal damage. Patients should be educated on the importance of monitoring and limiting sodium to <5 g/day^[8] in their diet to support overall kidney health.

Regular monitoring and follow-up

Continuous monitoring and regular follow-up are essential components of managing diabetic urinary microalbumin. Periodic assessments of kidney function, blood pressure, and glycemic control allow physicians to adjust treatment plans based on individual responses and disease progression.

To conclude, diabetic urinary microalbumin serves as an early warning sign for kidney dysfunction in individuals with diabetes. Detecting microalbuminuria and implementing timely treatment strategies are paramount to preventing the progression of diabetic nephropathy and associated complications. A comprehensive approach that includes glycemic control, blood pressure management, lifestyle modifications, renoprotective medications, dietary sodium restriction, and regular monitoring is essential for the holistic care of individuals with diabetic urinary microalbuminuria. There is a lack of awareness among diabetic patients and physicians on nephropathy,^[9] which should be targeted in the diagnosis of the disease. The age-old dictum of “prevention is better than cure” suits the most for diabetic kidney disease.

S. Parthasarathy¹, A. K. Das²

¹Professor, Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India, ²Dean, Academics, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India

Address for correspondence: Dr. S. Parthasarathy, Professor, Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry (Main) Campus, Pillaiyarkuppam, Puducherry - 607 402, India.
E-mail: sbvj@sbvu.ac.in

REFERENCES

1. Asghar S, Asghar S, Mahmood T, Bukhari SM, Mumtaz MH, Rasheed A. Microalbuminuria as the Tip of iceberg in type 2 diabetes mellitus: Prevalence, risk factors, and associated diabetic complications. *Cureus* 2023;15:e43190.
2. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: Worldwide difference of prevalence and risk factors. *J Nephropharmacol* 2016;5:49-56.
3. Suchitra MR, Monica A, Balachandar S, Parthasarathy S. Community assessment of incidence of quantitative microalbuminuria at the time of first diagnosis of type 2 diabetes mellitus – Kumbakonam urban – Rural epidemiological study – Kures 9. *Asian J Pharm Res Health Care* 2022;14:243-6.
4. Bakris GL. Microalbuminuria: What is it? Why is it important? What should be done about it? *J Clin Hypertens (Greenwich)* 2001;3:99-102.
5. Davis KN, Hines AE, Schaefer MC, Naseman KW. Protecting the kidneys: Update on therapies to treat diabetic nephropathy. *Clin Diabetes* 2022;40:305-11.
6. Ural C, Celik A, Ozbal S, Guneli E, Arslan S, Ergur BU, *et al.* The renoprotective effects of taurine against diabetic nephropathy via the p38 MAPK and TGF- β /Smad2/3 signaling pathways. *Amino Acids* 2023;55:1665-77.
7. Onyenwenyi C, Ricardo AC. Impact of lifestyle modification on diabetic kidney disease. *Curr Diab Rep* 2015;15:60.
8. Hodson EM, Cooper TE. Altered dietary salt intake for preventing diabetic kidney disease and its progression. *Cochrane Database Syst Rev* 2023;1:CD006763.
9. Chu L, Bhogal SK, Lin P, Steele A, Fuller M, Ciaccia A, *et al.* AWAREness of diagnosis and treatment of chronic kidney disease in adults with type 2 diabetes (AWARE-CKD in T2D). *Can J Diabetes* 2022;46:464-72.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:



Website:

<https://journals.lww.com/sbvj/>

DOI:

10.4103/SBVJ.SBVJ_5_24

How to cite this article: Parthasarathy S, Das AK. Detection and treatment of diabetic urinary microalbumin: The need of the hour. *SBV J Basic Clin Appl Health Sci* 2024;7:1-2.

Received: 01-06-2024,

Revised: 03-06-2024,

Accepted: 03-06-2024,

Published: 09-08-2024.